Skip to main content

A miniature Bio-photonics Companion Diagnostics platform for reliable cancer diagnosis and treatment monitoring.

Objetivo

Current diagnostic options for cancer treatment monitoring rely on imaging techniques and cannot guarantee proper assessment of therapeutic response. This project aims to develop a disruptive Point of Care (PoC) device for cancer early diagnosis and treatment monitoring as a companion diagnostics tool. One of the scientific breakthroughs of this project is the development of a “cancer stem cells” detection platform by virtue of expression of the cancer stem cell-specific transcription factor TWIST1, which controls the expression of the bloodstream circulating biomarkers POSTN, PCOLCE and TGBI. Cancer stem cells represent the most aggressive/tumorigenic cell compartment within tumors.
BIOCDx will combine advanced concepts from the photonic, nano-biochemical, micro-fluidic and reader/packaging platforms aiming to overcome limitations related to detection reliability, sensitivity, specificity, compactness and cost issues. BIOCDx will rely on ultrasensitive, photonic elements based on an array of 8 asymmetric MZI waveguides fabricated by TriPlex technology on silicon nitride substrates and will achieve a 100 fold improvement –with respect to current technologies- of sensitivity (<10-8 RIU). BIOCDx will emlploy a smart concept of signal multiplexing for lowering the number of photodetectors required in multi-analyte detection and allowing for a substantial reduction of chip size. A sandwich assay, enhanced with nanoparticles, will be developed, based on the use of two antibodies per protein, to detect all three circulating proteins. This will enhance the limit of detection (LOD) close to femtomolar and the reliability. BIOCDx photonic, nano-biochemical, fluidics and packaging platforms will be integrated into a portable, desktop PoC device. Its validation in preclinical and clinical setting will be performed in three cancer types: breast cancer, hormone-independent prostate cancer and melanoma.

Convocatoria de propuestas

H2020-ICT-2016-1
Consulte otros proyectos de esta convocatoria

Coordinador

INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
Dirección
Patission Str. 42
10682 Athina
Greece
Tipo de actividad
Research Organisations
Aportación de la UE
€ 700 985

Participantes (6)

LIONIX INTERNATIONAL BV
Países Bajos
Aportación de la UE
€ 559 500
Dirección
Hengelosestraat 500
7521 AN Enschede
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LRE MEDICAL GMBH
Alemania
Aportación de la UE
€ 710 000
Dirección
Hofer Strasse 5
86720 Nordlingen
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Suiza
Aportación de la UE
€ 0
Dirección
Rue Jaquet Droz 1
2000 Neuchatel
Tipo de actividad
Research Organisations
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
Aportación de la UE
€ 550 125
Dirección
Soranou Efesiou 4
115 27 Athina
Tipo de actividad
Research Organisations
FUTURE DIAGNOSTICS SOLUTIONS BV
Países Bajos
Aportación de la UE
€ 328 125
Dirección
Nieuweweg 279
6603 BN Wijchen
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LEAD PHARMA HOLDING BV
Países Bajos
Aportación de la UE
€ 315 000
Dirección
Kloosterstraat 9
5349 AB Oss
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)